MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
2.935
+0.295
+11.17%
Opening 11:14 04/22 EDT
OPEN
3.080
PREV CLOSE
2.640
HIGH
3.350
LOW
2.900
VOLUME
241.80K
TURNOVER
0
52 WEEK HIGH
5.24
52 WEEK LOW
1.040
MARKET CAP
33.56M
P/E (TTM)
-0.8228
1D
5D
1M
3M
1Y
5Y
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Healthcare On the Move: Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers. S&P 500 Health Care Sector +0.08% to 1620.1. Moolec Science SA, NKGen Biotech, ProKidney among top gainers.
Seeking Alpha · 1h ago
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Susquehanna raised the price target for Occidental Petroleum Corporation from $70 to $81 on Friday. Chardan Capital increased Ocugen, Inc. Price target from $4 to $5. Keybanc boosted the price targets for Alphabet Inc. And ConocoPhillips.
Benzinga · 3h ago
PROTARA THERAPEUTICS <TARA.O>: OPPENHEIMER RAISES TARGET PRICE TO $30 FROM $26
Reuters · 3h ago
Weekly Report: what happened at TARA last week (0415-0419)?
Weekly Report · 4h ago
Protara Therapeutics Price Target Raised to $30.00/Share From $26.00 by Oppenheimer
Dow Jones · 4h ago
Protara Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 4h ago
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer
TipRanks · 4h ago
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $30
Benzinga · 4h ago
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.